Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n°159

AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer

Posted by fidest press agency su mercoledì, 3 gennaio 2018

cancerAgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging. The study, by scientists at AgeX and BioTime, in collaboration with Insilico Medicine, utilized artificial intelligence (AI) technology to parse millions of gene expression data points to decipher the complex mechanisms controlling natural tissue regeneration. The results, published in the peer-reviewed scientific journal Oncotarget, showed that the candidate genes are expressed differently in tissues early in development when they are capable of regeneration compared to later in life when regeneration can no longer take place. Surprisingly, some of the genes, including one highlighted in the study, COX7A1, displayed a rare profile of being nearly universally dysregulated in diverse types of cancer. The discoveries may lead to novel strategies to induce Tissue Regeneration (iTRTM) in the context of trauma or age-related degenerative disease, as well as treat and diagnose cancer.“It is rare to find genes implicated in tissue regeneration, let alone with abnormal expression in so many diverse cancer types such as those of the breast, lung, kidney, bone, and muscle,” said Michael D. West, PhD, CEO of AgeX and co-CEO of BioTime. “AgeX has certain rights to use the associated patent applications and to commercialize related therapeutic and diagnostic applications. Since we believe unlocking the natural ability of the human body to regenerate tissues afflicted with degenerative disease is a very large market opportunity, we are aggressively developing products using the technology.”A short video is available online describing the discovery and its implication for product development at AgeX. Included in the video is a discussion of an iTR product designated RenelonTM, which, in its first generation form, utilizes a repurposed drug and may therefore have a relatively short development timeline.“The embryonic-to-fetal transition (EFT) deciphered in this study is emerging as a wonderful new arena in which to explore the enhancement of regenerative capacity in old age, which is the core of AgeX’s mission,” said Aubrey de Grey, PhD, VP of New Technology Discovery at AgeX. “The discovery of a subunit of the respiratory chain as a key EFT marker dovetails this research fascinatingly with age-related changes in mitochondrial function, which have long been a priority in the anti-aging field and in my own work.”“BioTime and AgeX Therapeutics are at the forefront of regenerative medicine,” commented Alex Zhavoronkov, PhD, CEO of Insilico Medicine. “By utilizing their heavy investment in large-scale, highly-controlled experiments and their unique expertise in regenerative medicine we managed to develop the AI-powered system for cell and tissue sample profiling. We utilized this system to identify the important genes implicated in the EFT, and possibly in aging. This collaboration started in 2015 when deep leaning methods were in their infancy and required two years to diligently validate the outcomes. We learned that domain expertise is just as important as expertise in AI.”

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: